Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aptose Biosciences announced participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York City from September 12-14, 2022. Dr. William G. Rice, Chairman and CEO, will present on September 13 at 11:30 a.m. ET. Additionally, one-on-one meetings with management will be available. Aptose focuses on developing oral kinase inhibitors for hematologic malignancies, with two key investigational drugs in clinical trials. For more details, visit www.aptose.com.
- None.
- None.
SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held in-person and virtually September 12-14, 2022, in New York City.
Dr. William G. Rice, Chairman, President and CEO of Aptose, will deliver the Company presentation on Tuesday, September 13, 2022, at 11:30 a.m. ET, and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, please contact your conference representative.
| H.C. Wainwright 24th Annual Global Investment Conference | |
| Date: | September 13, 2022 |
| Presentation Time: | 11:30 a.m. ET |
| Format: | Live Presentation, Webcast |
| Speaker: | William G. Rice, PhD, Chairman, President and Chief Executive Officer |
| Webcast Link: | Click here |
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the Company’s growth, plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
| For further information, please contact: | |
| Aptose Biosciences Inc. | LifeSci Advisors, LLC |
| Susan Pietropaolo | Dan Ferry, Managing Director |
| Investor Relations | 617-535-7746 |
| 201-923-2049 | Daniel@LifeSciAdvisors.com |
| spietropaolo@aptose.com | |
FAQ
What date will Aptose present at the H.C. Wainwright conference?
Who will represent Aptose at the investment conference?
What is the focus of Aptose Biosciences?
Which drugs is Aptose developing for hematologic malignancies?
Is the H.C. Wainwright conference in-person or virtual?
